keymaker-u01 umbrella master study: studies of investigational agents with either pembrolizumab (mk-3475) alone or with pembrolizumab plus chemotherapy in participants with non-small cell lung cancer (nsclc) (mk-3475-u01/keymaker-u01)

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this study is referred to as the "umbrella master protocol" for pembrolizumab (mk-3475) in the treatment of non-small cell lung cancer (nsclc). this pembrolizumab nsclc umbrella master protocol uses a platform design and consists of this master screening study and seven substudies. each substudy will enroll a different population of nsclc participants. the goal of this umbrella master protocol is to screen potential participants with nsclc for enrollment into 1 of 7 substudies. participants must first enroll in this pembrolizumab master protocol study and undergo screening for nsclc that will be used to assign them to participation in 1 of 7 pembrolizumab substudies.

the following 7 pembrolizumab substudies will evaluate the efficacy of different investigational agents in combination with pembrolizumab given in sequence or in combination with pembrolizumab plus chemotherapy: * keymaker-u01 substudy 01a: a phase 1/2, umbrella study with rolling arms of investigational agents, with pembrolizumab with or without chemotherapy in treatment-naive participants with stage iv non-small cell lung cancer (nsclc) (mk-3475-01a) - nct04165070 * keymaker-u01 substudy 2: a phase 2, umbrella study with rolling arms of investigational agents in combination with pembrolizumab in treatment naïve patients with pd-l1 positive advanced non-small cell lung cancer (nsclc) (mk-3475-01b) - nct04165083 * keymaker-u01 substudy 3: a phase 2, umbrella study with rolling arms of investigational agents in combination with pembrolizumab in patients with advanced non-small cell lung cancer (nsclc) previously treated with anti-pd-(l)1 therapy (mk-3475-01c) - nct04165096 * keymaker-u01 substudy 01e: a phase 2 umbrella study with rolling arms of investigational agents with or without chemotherapy in combination with pembrolizumab in treatment of participants with newly diagnosed resectable stages ii-iiib (n2) non-small cell lung cancer (nsclc) (mk-3475-01e) - nct06788912 * keymaker-u01 substudy 01g: a phase 2, umbrella study with rolling arms of investigational agents in combination with pembrolizumab with or without platinum-based chemotherapy in treatment-naïve participants with stage iv non-small cell lung cancer (nsclc) (mk-3475-01g) - nct06731907 * keymaker-u01 substudy 01f: a phase 1b/2 umbrella study with rolling arms of investigational agents for second-line treatment of participants with advanced or metastatic nonsquamous non-small cell lung cancer (nsclc) with kras g12c mutations * keymaker-u01 substudy 01h: a phase 2, randomized, umbrella study with rolling arms of investigational agents in participants with previously treated stage iv nonsquamous non-small cell lung cancer (nsclc) (mk-3475-01h) - nct06780085 * keymaker-u01 substudy 01i: a phase 2, randomized, umbrella study with rolling arms of investigational agents in participants with previously treated stage iv squamous non-small cell lung cancer (nsclc) (mk-3475-01i) - nct06780098

Eligibility criteria:
inclusion criteria: * has histologically- or cytologically-confirmed diagnosis of stage iv squamous or nonsquamous nsclc * participants with nonsquamous nsclc who are not eligible for an approved targeted therapy * is able to to provide archival tumor tissue sample collected either within 5 years or within the interval from completion of last treatment but before entering the screening period or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated obtained within 90 days of treatment initiation * has not received prior systemic treatment for their metastatic nsclc * has adequate organ function within 10 days of initiation of study treatment * male participants must agree to use contraception and should refrain from donating sperm during the treatment period exclusion criteria: * has preexisting neuropathy that is moderate in intensity * has received a live or live-attenuated vaccine within 30 days before the first dose of study treatment. any licensed covid-19 vaccine (including for emergency use) in a particular country is allowed as long as they are messenger ribonucleic acid (mrna) vaccines, adenoviral vaccines, or inactivated vaccines. investigational vaccines (ie, those not licensed or approved for emergency use) are not allowed * is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study treatment * has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment * has an active autoimmune disease that has required systemic treatment in the past 2 years * has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease * has an active infection requiring systemic therapy * has a known history of hiv infection * has a known history of hepatitis b or known active hepatitis c virus infection * has had an allogenic tissue/solid organ transplant

Keywords: programmed cell death-1 (pd1, pd-1) programmed death-ligand 1 (pdl1, pd-l1)